Shop Easy Usa Ultram

Research highlights include how we see faces in our dreams, understanding how young and old adults learn, helping stroke survivors speak using fMRI, an explanation about autism and facial recognition and ways to possibly forestall Parkinson's disease.

Pharmos Corporation (Nasdaq: PARS) announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized, double-blinded, placebo controlled study evaluated the safety and efficacy of the Company's 3% Diclofenac Diethanolamine NanoEmulsion cream in 104 patients with chronic pain due to osteoarthritis of the knee.

Pharmos Corporation (Nasdaq: PARS) announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized, double-blinded, placebo controlled study evaluated the safety and efficacy of the Company's 3% Diclofenac Diethanolamine NanoEmulsion cream in 104 patients with chronic pain due to osteoarthritis of the knee.

Pharmos Corporation (Nasdaq: PARS) announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized, double-blinded, placebo controlled study evaluated the safety and efficacy of the Company’s 3% Diclofenac Diethanolamine NanoEmulsion cream in 104 patients with chronic pain due to osteoarthritis of the knee.

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience service provider and drug development Company, and Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a leading international biopharmaceutical company, announce that NeuroSolutions is presenting further pivotal pre-clinical efficacy data for NSL-043/SD118. This investigational drug is a potential therapy for neuropathic pain and has successfully completed Phase I clinical studies and is now ready for Phase II studies.

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience service provider and drug development Company, and Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a leading international biopharmaceutical company, announce that NeuroSolutions is presenting further pivotal pre-clinical efficacy data for NSL-043/SD118. This investigational drug is a potential therapy for neuropathic pain and has successfully completed Phase I clinical studies and is now ready for Phase II studies.

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) today announces that it has successfully completed a Phase I study with its intravenous sedative/anaesthetic CNS 7056. The study was completed ahead of schedule because the target criterion, more than 50% of the volunteers reaching loss of consciousness for more than 5 minutes, was reached in the 9th of the 10 planned cohorts.

A recent clinical study found that patients experienced nearly a 70% reduction in pain when MPM Medical Inc.'s Regenecare HA® hydrogel was used prior to and during the changing of their wound dressings. The finding comes at a time when a cross-section of American thought leaders are calling the lack of proper pain management a national healthcare crisis. In answer, members of Congress have united to sponsor the National Pain Care Policy Act of 2008 (H.R.

A recent clinical study found that patients experienced nearly a 70% reduction in pain when MPM Medical Inc.'s Regenecare HA® hydrogel was used prior to and during the changing of their wound dressings. The finding comes at a time when a cross-section of American thought leaders are calling the lack of proper pain management a national healthcare crisis. In answer, members of Congress have united to sponsor the National Pain Care Policy Act of 2008 (H.R.

Applied Pharma Research sa (APR), and Fidia Farmaceutici SpA (Fidia) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for the development of a 140mg Diclofenac Sodium Matrix Patch for the topical treatment of acute pain due to minor strains, sprains and contusions.